Liquidia (NASDAQ:LQDA) Director Stephen Bloch Sells 85,062 Shares

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 85,062 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $71.44, for a total value of $6,076,829.28. Following the completion of the sale, the director owned 980,073 shares in the company, valued at approximately $70,016,415.12. This represents a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Liquidia Trading Down 5.3%

LQDA stock opened at $68.01 on Wednesday. Liquidia Corporation has a 1-year low of $11.85 and a 1-year high of $73.22. The firm has a market cap of $6.05 billion, a P/E ratio of 485.82 and a beta of 0.58. The business’s 50 day moving average is $51.14 and its 200-day moving average is $41.50. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.11. The company had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The firm’s quarterly revenue was up 4187.1% on a year-over-year basis. Equities analysts anticipate that Liquidia Corporation will post 2.97 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. acquired a new position in Liquidia during the 4th quarter worth $25,000. Covestor Ltd lifted its holdings in Liquidia by 41.9% during the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after buying an additional 359 shares in the last quarter. Skandinaviska Enskilda Banken AB publ acquired a new position in Liquidia during the 3rd quarter worth $30,000. FNY Investment Advisers LLC acquired a new position in Liquidia during the 3rd quarter worth $34,000. Finally, NewEdge Advisors LLC acquired a new position in Liquidia during the 2nd quarter worth $25,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on LQDA shares. Needham & Company LLC increased their target price on Liquidia from $54.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Oppenheimer set a $75.00 target price on Liquidia in a report on Friday, June 5th. BTIG Research increased their target price on Liquidia from $50.00 to $59.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Wells Fargo & Company increased their target price on Liquidia from $51.00 to $62.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. Finally, HC Wainwright increased their target price on Liquidia from $67.00 to $75.00 and gave the stock a “buy” rating in a report on Friday, June 5th. Three equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $60.29.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).